Marker composition for diagnosing or predicting prognosis of lung cancer based on exosome overexpressing gcc2 gene or protein

Abstract

Described herein is a composition for diagnosing or predicting the prognosis of lung cancer. The composition includes a primer, probe, or antibody that specifically binds to a GRIP and coiled-coil domain-containing protein (GCC2) gene or protein in an exosome.

1 . A marker composition for diagnosing or prognosing lung cancer, the composition containing exosome overexpressing a GCC2 (GRIP and coiled-coil domain-containing protein) protein. 
     
     
         2 . A composition for diagnosing or prognosing lung cancer, the composition containing a primer or a probe that specifically binds to a GCC2 (GRIP and coiled-coil domain-containing protein) gene in exosome. 
     
     
         3 . A composition for diagnosing or prognosing lung cancer, the composition containing an antibody that specifically binds to a GCC2 (GRIP and coiled-coil domain-containing protein) protein in exosome. 
     
     
         4 . A kit for diagnosing or prognosing lung cancer, the kit containing the composition of  claim 2 . 
     
     
         5 . The kit of  claim 4 , wherein the kit includes at least one selected from a group consisting of an RT-PCR kit, a microarray chip kit, a DNA kit and a protein chip kit. 
     
     
         6 . A method for providing information needed to diagnose or prognose lung cancer, the method including:
 (a) separating an exosome from a biological sample; and   (b) measuring an expression level of a GCC2 (GRIP and coiled-coil domain-containing protein) gene or protein in the exosome.   
     
     
         7 . The method of  claim 6 , wherein the biological sample includes at least one selected from a group consisting of whole blood, serum, plasma, saliva, urine, sputum, lymph and cell. 
     
     
         8 . A method for screening a lung cancer therapeutic agent, the method including:
 (a) treating a biological sample collected from a lung cancer patient with a candidate substance for a lung cancer therapeutic agent;   (b) separating exosome from the biological sample; and   (c) measuring an expression level of a GCC2 (GRIP and coiled-coil domain-containing protein) gene or protein in the exosome.   
     
     
         9 . A kit for diagnosing or prognosing lung cancer, the kit containing the composition of  claim 3 . 
     
     
         10 . The kit of  claim 9 , wherein the kit includes at least one selected from a group consisting of an RT-PCR kit, a microarray chip kit, a DNA kit and a protein chip kit.